Home/Filings/4/A/0001654954-20-000350
4/A//SEC Filing

Lumira Capital Investment Management Inc. 4/A

Accession 0001654954-20-000350

CIK 0001540159other

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 10:11 AM ET

Size

19.2 KB

Accession

0001654954-20-000350

Insider Transaction Report

Form 4/AAmended
Period: 2020-01-08
van der Velden Peter
Director10% Owner
Transactions
  • Award

    Common Shares

    2020-01-08$3.20/sh+128,722$411,9101,833,066 total(indirect: By IRA)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+96,54296,542 total(indirect: By IRA)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (96,542 underlying)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+64,36264,362 total(indirect: By IRA)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (64,362 underlying)
  • Award

    Common Shares

    2020-01-08$3.20/sh+11,903$38,090169,502 total(indirect: By IRA)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+8,9288,928 total(indirect: By IRA)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (8,928 underlying)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+5,9525,952 total(indirect: By IRA)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (5,952 underlying)
Transactions
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+5,9525,952 total(indirect: By IRA)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (5,952 underlying)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+8,9288,928 total(indirect: By IRA)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (8,928 underlying)
  • Award

    Common Shares

    2020-01-08$3.20/sh+11,903$38,090169,502 total(indirect: By IRA)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+64,36264,362 total(indirect: By IRA)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (64,362 underlying)
  • Award

    Common Shares

    2020-01-08$3.20/sh+128,722$411,9101,833,066 total(indirect: By IRA)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+96,54296,542 total(indirect: By IRA)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (96,542 underlying)
Footnotes (6)
  • [F1]The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
  • [F2]The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
  • [F3]This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
  • [F4]Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
  • [F5]Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.
  • [F6]Amended to reflect acquisition from the issuer.

Issuer

Edesa Biotech, Inc.

CIK 0001540159

Entity typeother
IncorporatedCanada (Federal Level)

Related Parties

1
  • filerCIK 0001702636

Filing Metadata

Form type
4/A
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 10:11 AM ET
Size
19.2 KB